PMID- 23448382
OWN - NLM
STAT- MEDLINE
DCOM- 20130910
LR  - 20211021
IS  - 1471-230X (Electronic)
IS  - 1471-230X (Linking)
VI  - 13
DP  - 2013 Feb 28
TI  - Cost and burden of gastroesophageal reflux disease among patients with persistent 
      symptoms despite proton pump inhibitor therapy: an observational study in France.
PG  - 39
LID - 10.1186/1471-230X-13-39 [doi]
AB  - BACKGROUND: Gastrointestinal reflux disease (GERD) is a common disorder that 
      negatively impacts health-related quality of life (HRQL) and work productivity. 
      Many patients have only a partial response to proton pump inhibitor (PPI) therapy 
      and continue to experience GERD symptoms despite optimized treatment. This 
      observational study aimed to provide information on symptoms, HRQL, resource 
      usage, costs and treatment pathways associated with partial response to PPI 
      therapy in French patients with GERD. METHODS: Patients with partial response to 
      PPI therapy, defined as persistent GERD symptoms >/=3 days/week despite optimized 
      treatment with a PPI, were recruited for this 12-month observational study. GERD 
      symptoms, HRQL, work productivity and resource use were assessed by patient 
      surveys. Costs were calculated based on lost work productivity and resource use. 
      RESULTS: The patient population (n=262; mean age, 54 years; 40% men) carried a 
      significant symptom burden, with 98% of patients having moderate-to-severe GERD 
      symptoms and 65% of patients experiencing daily symptoms at baseline. HRQL and 
      work productivity were significantly impaired, with a greater degree of 
      impairment in patients with higher symptom burden. The mean total cost per 
      patient over the 12-month follow-up period was euro5237, of which euro4674 (89%) was 
      due to lost work productivity. CONCLUSIONS: Partial response to PPI therapy for 
      GERD is associated with a high symptom burden, significant impairment of HRQL and 
      work productivity, and substantial GERD-related costs.
FAU - Bruley des Varannes, Stanislas
AU  - Bruley des Varannes S
AD  - Institut des Maladies de l'Appareil Digestif, University Hospital - CHU Hotel 
      Dieu, Place A Ricordeau, Nantes Cedex, 44093, France. 
      stanislas.bruleydesvarannes@chu-nantes.fr
FAU - Lofman, Helena Granstedt
AU  - Lofman HG
FAU - Karlsson, Maria
AU  - Karlsson M
FAU - Wahlqvist, Peter
AU  - Wahlqvist P
FAU - Ruth, Magnus
AU  - Ruth M
FAU - Furstnau, Mary Lou
AU  - Furstnau ML
FAU - Despiegel, Nicolas
AU  - Despiegel N
FAU - Stalhammar, Nils-Olov
AU  - Stalhammar NO
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20130228
PL  - England
TA  - BMC Gastroenterol
JT  - BMC gastroenterology
JID - 100968547
RN  - 0 (Proton Pump Inhibitors)
SB  - IM
MH  - *Cost of Illness
MH  - Female
MH  - France/epidemiology
MH  - Gastroesophageal Reflux/*drug therapy/*economics/epidemiology
MH  - Health Care Costs/statistics & numerical data/*trends
MH  - Health Resources/statistics & numerical data
MH  - Humans
MH  - Longitudinal Studies
MH  - Male
MH  - Middle Aged
MH  - Proton Pump Inhibitors/*therapeutic use
MH  - Quality of Life/psychology
MH  - Retrospective Studies
MH  - Treatment Outcome
MH  - Workload/statistics & numerical data
PMC - PMC3610279
EDAT- 2013/03/02 06:00
MHDA- 2013/09/11 06:00
PMCR- 2013/02/28
CRDT- 2013/03/02 06:00
PHST- 2012/08/22 00:00 [received]
PHST- 2013/02/21 00:00 [accepted]
PHST- 2013/03/02 06:00 [entrez]
PHST- 2013/03/02 06:00 [pubmed]
PHST- 2013/09/11 06:00 [medline]
PHST- 2013/02/28 00:00 [pmc-release]
AID - 1471-230X-13-39 [pii]
AID - 10.1186/1471-230X-13-39 [doi]
PST - epublish
SO  - BMC Gastroenterol. 2013 Feb 28;13:39. doi: 10.1186/1471-230X-13-39.